Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Share data with your provider
FDA-APPROVED INDICATIONS Type 2 diabetes As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus Limitations of use: has not been studied in patients with a history of pancreatitis TYPE 2 DIABETES RCT SURPASS-2 trial - Tirzepatide vs Semaglutide in Patients with Type 2 Diabetes, NEJM (2021) [PubMed abstract] The SURPASS-2 trial enrolled 1879 adults with type 2 diabetes who were inadequately controlled with metformin at a dose of at least 1500 mg per day Main inclusion criteria Age 18 years T2DM uncontrolled with metformin at 1500 mg/day A1C of 7 - 10.5% BMI 25 and stable for 3 months Main exclusion criteria Type 1 diabetes GFR 50 ng/L
The lot number on your COA matches the label on your vial giving you direct access to the same data we use for internal quality control
51,52 The effect of gender on the composition and function of the gut microbiota may also contribute to differences in TS symptoms and response to treatment
